Drug Profile

Umbilical cord-derived allogeneic mesenchymal stem cell therapy - Vitro Biopharma

Alternative Names: AlloRx; AlloRx stem cells^®

Latest Information Update: 05 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vitro Diagnostics
Developer The Foundation for Orthopaedics and Regenerative Medicine; Vitro Diagnostics
Class Mesenchymal stem cell therapies; Stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pitt-Hopkins syndrome
New Molecular Entity No

Phase III Osteoarthritis
Phase I/II COVID 2019 infections; Crohn's disease; Meniscus disorders; Pitt-Hopkins syndrome; Systemic lupus erythematosus
Phase I Multiple sclerosis
No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Angina pectoris; Autistic disorder; Cerebral palsy; Diabetes mellitus; Erectile dysfunction; Heart failure; Inflammatory bowel diseases; Interstitial cystitis; Osteoporosis; Parkinson's disease; Peripheral nervous system diseases; Peyronie's disease; Rheumatoid arthritis; Stroke; Systemic scleroderma; Traumatic brain injuries; Trigeminal neuralgia

05 Mar 2026 Umbilical cord derived allogenic mesenchymal stem cell therapy is still in phase I trials for Multiple sclerosis (In Children, In adults, In the elderly) in Antigua and Barbuda, Greece (IV)
28 Jan 2026 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (IV, Infusion)
28 Jan 2026 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (IV, Infusion)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com